Table 2.

Causes of death in participants who did and did not reach chronic dialysis

	Dapagliflozin		Placebo		Total
	n (%)	Event rate (100 patient-years)	n (%)	Event rate (100 patient-years)	n (%)	Event rate (100 patient-years)
Overall mortality	101/2152 (4.7)	2.2	146/2152 (6.8)	3.1	247/4304 (5.7)	2.6
Without chronic dialysis, n	2084		2053		4137
All-cause mortality	89 (4.3)	1.9	121 (5.9)	2.6	210 (5.1)	2.2
Cardiovascular death	35 (1.7)	0.7	44 (2.1)	0.9	79 (1.9)	0.8
Non-cardiovascular death	31 (1.5)	0.7	48 (2.3)	1.0	79 (1.9)	0.8
Undetermined cause of death	23 (1.1)	0.5	29 (1.4)	0.6	52 (1.3)	0.5
With chronic dialysis, n	68		99		167
All-cause mortality	12 (17.6)	8.6	25 (25.3)	13.4	37 (22.2)	11.4
Cardiovascular death	6 (8.8)	3.9	6 (6.1)	2.6	12 (7.2)	3.1
Non-cardiovascular death	5 (7.4)	3.2	18 (18.2)	9.0	23 (13.8)	6.5
Undetermined cause of death	1 (1.5)	0.6	1 (1.0)	0.4	2 (1.2)	0.5